MedTrace Logo

Tapentadol Versus Oxycodone - a Mechanism-based Treatment Approach in Neuropathic Pain

NCT01458015 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2025-01-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to elucidate whether the additional mechanism of analgesia, i.e. reuptake inhibition of norepinephrine, of tapentadol leads to a change in different pain signs and symptoms in comparison to oxycodone.

Conditions

Interventions

DRUG

tapentadol, oxycodone

tapentadol pr 100-500 mg oxycodone cr 20-120mg

Sponsors & Collaborators

  • University Hospital Schleswig-Holstein

    lead OTHER

Principal Investigators

  • Ralf Baron, Prof. Dr. · Head of Unit of Neuropathic Pain Research and Therapy, Department of Neurology, University Clinic Kiel

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01458015 on ClinicalTrials.gov